Atrial Fibrillation in PARTNER
between ventricular rate and mortality in AF patients after TAVR in the Placement of AoRTic TraNscathetER Valve (PARTNER) trial.
Methods

Study Population
The design of the PARTNER trial has been previously described. 21, 22 Briefly, it enrolled patients with severe aortic stenosis who were deemed to be either high risk for SAVR (cohort A) or nonsurgical candidates (cohort B). Patients in cohort A were randomized to either SAVR or aortic valve replacement by the transfemoral) or transapical approach. Patients in cohort B with adequate femoral access were randomized to transfemoral TAVR or standard medical therapy. After completion of the randomized trial enrollment, patients were enrolled in a continued access registry for either transapical or transfemoral TAVR. All patients who underwent TAVR had implantation of an Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA). The date of data extraction was February 2013.
Patients in the PARTNER trial had ECG, echocardiogram, and clinical evaluation performed at baseline, discharge, 30 days, 6 months, and 1 year post TAVR. Patients were included in this analysis only if they had undergone TAVR as part of either the randomized trial or the nonrandomized continued access registry and had baseline and discharge ECGs available for analysis.
The study was approved by the Institutional Review Board at each participating site, and all patients provided written informed consent.
End Points
All baseline, discharge, 30 days, 6 months, and 1 year ECG and echocardiograms were interpreted in independent core laboratories. AF was defined as AF or atrial flutter/tachycardia that was present on the baseline or discharge ECG. Patients were subdivided into 4 categories: patients with baseline sinus rhythm (SR) and discharge ECG showing SR, patients with baseline SR/discharge AF, patients with baseline AF/discharge AF, and patients with baseline AF/discharge SR. Clinical outcomes were then compared among the groups; the baseline AF/discharge SR group was not analyzed because of low number of patients in that group. Subgroup analyses were performed based on ventricular rate during AF (<90 versus ≥90 bpm) and TAVR type (transfemoral versus transapical).
The primary end point of this analysis was overall mortality. Secondary clinical end points included cardiovascular (CV) mortality, rehospitalization, stroke/transient ischemic attack (TIA), major bleeding, major vascular event, renal failure requiring dialysis, bradyarrhythmias requiring new pacemaker implantation, and change in 6-minute walk test distance result (meters), as described in the PARTNER trial protocol. 22, 29, 30 All end points were measured at 30 days and 1 year. All adverse clinical events were adjudicated by an independent clinical events committee.
Statistical Analysis
All analysis was performed on the as-treated population, with results presented as median (25th-75th percentile) or percentages as appropriate. Continuous variables were compared across groups by the Kruskal-Wallis test, and categorical variables were compared using χ 2 or Fisher exact test as appropriate. Event rates were reported as Kaplan-Meier estimates at 1 year and compared between groups using the log-rank test. Individual subgroup comparisons are presented if the overall P value for the comparison across the 3 groups is ≤0.05.
To adjust for multiple comparisons, a Bonferroni corrected P value of 0.0167 is used to indicate statistical significance when summarizing pair wise comparisons. Mortality at 30 days and 1 year were modeled using Cox regression. The model included clinically relevant variables, such as age, sex, and Society of Thoracic Surgeons (STS) risk score along with bleeding requiring transfusion, bradyarrhythmia, requiring pacemaker implantation, myocardial infarction, renal failure requiring dialysis, and stroke, all defined by discharge. Because of the limited events at day 30, only the variables defined at discharge and STS risk score were included in the model. Landmark analysis was performed using 30 days as time = 0 to analyze the association between 30-day survival and 1-year mortality. Statistical analyses were performed using SAS software, versions 9.2 and 9.4 (SAS Institute, Cary, NC).
Results
Patient Population and Characteristics
The study population included 1879 patients from cohort A, cohort B, and the continued access registry of the PARTNER trial ( Figure 1 ), 1097 of whom underwent transfemoral TAVR and 782 of whom underwent transapical TAVR. From this group, 1262 manifested SR at baseline/SR at discharge, 113 had SR baseline/AF discharge, 470 had AF baseline/AF discharge, and 34 had AF baseline/SR discharge. The latter group of 34 patients with AF baseline/SR discharge was not included in further analyses given their relatively low representation.
Baseline characteristics of each group are included in Table 1 . Age ranged from 85 to 86 years across groups. STS score ranged from 10.5 to 11.1 and was highest in the baseline AF/discharge AF group. Notably, when compared with baseline SR/discharge SR patients, those patients with baseline AF/discharge AF were more likely to be male and had a higher STS score. Patients with baseline AF/discharge AF had higher rates of pulmonary hypertension and pacemakers compared with baseline SR/discharge SR patients. There were no significant differences among groups for body mass index, diabetes mellitus, hypertension, congestive heart failure, prior myocardial infarction, or stroke/TIA. Baseline ECG and echocardiogram findings are in Table 2 . Notable baseline ECG findings include significantly more first degree atrioventricular block in the baseline SR/discharge AF patients (versus the baseline SR/discharge SR patients). There
WHAT IS KNOWN
• Patients undergoing transcatheter aortic valve replacement (TAVR) have relatively high rates of atrial fibrillation (AF).
• Studies in surgical aortic valve replacement patients have noted that the presence of AF is correlated with worsened outcomes, including higher mortality.
• A better understanding of the degree to which AF impacts on outcomes including mortality would have clinical utility.
WHAT THE STUDY ADDS
• For TAVR patients, the presence of AF at discharge, and especially the conversion to AF by discharge, is associated with increased mortality at 30-day and 1-year and repeat hospitalizations at 1-year.
• For those TAVR patients with AF, there is an association between higher ventricular rates >90 bpm and mortality.
• Patients with AF after TAVR also have higher rates of renal failure requiring dialysis and permanent pacemaker implantation.
were no statistically significant differences in rates of interventricular conduction defect, right bundle branch block, or left bundle branch block. Baseline echocardiograms demonstrated a significantly lower left ventricular ejection fraction in patients with baseline AF/discharge AF (55.0%) versus the baseline SR/discharge SR (57.5%) or the baseline SR/ discharge AF (58.6%) patients. Compared with the baseline SR/discharge SR patients, patients with baseline AF/discharge AF were also more likely to have at least moderate mitral regurgitation.
Clinical Outcomes
Thirty-day outcomes are listed in Table 3 . Both all-cause mortality (14.2%) and CV mortality (8.3%) were highest in the baseline SR/discharge AF group. There were no significant differences in other end points including rehospitalization, stroke/TIA, major bleeding, and major vascular complications. Requirement for permanent pacemaker placement was highest at 12.7% in the baseline SR/discharge AF group.
Patients discharged in AF had a longer length of stay than patients who presented and remained in SR by discharge (6 versus 7 days, P=0.0004 across all groups).
At 1 year, the percent of patients in AF for each group was SR/SR=5.2%, SR/AF=27.9%, AF/AF=79.8%, P<0.0001 for all comparisons. One-year outcomes based on Kaplan-Meier analysis demonstrated significantly higher mortalities in the baseline SR/discharge AF (35.7%) group and the baseline AF/ discharge AF group (29.9%) compared with the baseline SR/ discharge SR group (15.8%; Figure 2 ). The baseline AF/discharge AF group had the highest 1-year CV mortality (21%) and rehospitalization rate (26.7%), although the baseline SR/ discharge SR group had the lowest rates of all-cause mortality, CV mortality, and rehospitalization. In landmark analysis that included those patients surviving at 30 days, rhythm status remained a predictor of outcomes.
Secondary Outcomes
Thirty-day and 1-year outcomes are presented Tables 3  and 4 . Renal failure requiring dialysis and new pacemaker implantations were higher in the SR/AF group at both 30-day and 1-year. There was a nonsignificant trend for least improvement in 6-minute walk test distance in the SR/AF group at both 30-day and 1-year. Although rates of stroke/TIA and major bleeding were not significantly different among groups, there were trends for increased events in the baseline SR/discharge AF groups at both 30-day and 1-year.
Multivariable Analysis of Predictors of Mortality
Predictors of 30-day and 1-year mortality are listed in Tables 5  and 6 . The development and maintenance of AF by discharge, as opposed to remaining in SR, was associated with higher 30-day mortality (hazard ratio [HR]=3.41 [1.78, 6.54];
P=0.0002). The development of AF by discharge (SR/AF) and presenting and remaining in AF at discharge (AF/AF) were each associated with increased 1-year mortality (HR=2.14 [1.45, 3.10] and HR=1.88 [1.50, 2.36], respectively).
Effect of Ventricular Rate during AF on Outcomes
Those patients discharged in AF with lower ventricular response (ie, <90 bpm) experienced less 1-year all-cause mortality (HR= 0.74 [0.55, 0.99]; P=0.04) and CV mortality (HR= 0.55, [0.38-0.79], P=0.0014), compared with those patients with ventricular response ≥90 bpm (Figure 3 ). There was no statistically significant difference in left ventricular ejection fraction at either 30-day (53%) or 1-year (55%) between groups. When comparing patients discharged in AF by ventricular response <90 versus ≥90 bpm, there were no statistically significant differences in rates of pacemakers at baseline (17.5% for <90 bpm versus 23.3% for ≥90 bpm, P=0.09) or placement by discharge (7.4% for <90 bpm versus 5.0% for ≥90 bpm, P=0.22).
Discussion
This study is the largest published analysis of the adverse impact of AF after TAVR on clinical outcomes. The main findings are as follows: 1) patients discharged in AF after TAVR in the PARTNER Trial have increased 30-day and 1-year mortality, CV mortality, and 1-year repeat hospitalization, particularly in those patients who convert from SR to AF between admission and discharge; 2) patients with AF after TAVR and ventricular response >90 bpm have higher 1-year mortality than those with ventricular response ≤90 bpm; 3) patients with AF after TAVR also have higher rates of renal failure requiring dialysis, permanent pacemaker implantation, and a nonsignificant increase for stroke/TIA. In particular, there is an early divergence of the survival curves before 3 months, revealing that development of AF by discharge is associated with increased early mortality. These findings provide further evidence that the presence of AF at discharge, particularly if not present at baseline, is not a benign condition in TAVR patients.
Previous studies have shown that AF is generally associated with worse outcomes in many CV disease states, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] including poorer outcomes in SAVR. [16] [17] [18] [19] [20] AF is also a known and relatively common complication of TAVR. 22, 28, 31, 32 Tanawuttiwat et al 28 noted an incidence of new AF equal to 53% in a single-center, retrospective study of 231 consecutive patients undergoing transaortic TAVR and 14% after transfemoral TAVR. Possible precipitating factors include CV and overall physical status related to the aged patient population with aortic stenosis, such as atrial fibrosis and larger atrial size, and sequelae of the TAVR procedure itself. Although reports of clinical outcomes of AF after TAVR are limited, the absence of AF is associated with better left ventricular ejection fraction recovery and improved mitral regurgitation, whereas the presence of AF is associated with increased stroke risk 22, 27, 28, 33 and mortality. 34 The causes of increased mortality in AF patients remain unclear. Although increased thromboembolic risk is often implicated, this study demonstrated AF remained a predictor of mortality even after adjusting for several clinical comorbidities including stroke. Other possible factors besides stroke/ TIA may include those associated with CV as well as overall functional status. With regard to CV status, this study noted that rapid ventricular response was associated with worse mortality outcomes for patients who developed AF by discharge, with possible reasons for the deleterious effects including reduced cardiac output and heart failure, including systolic as well as diastolic heart failure. Notably, left ventricular ejection fraction was worse in patients with AF/AF, and particularly, in patients discharged with AF and ventricular response ≥90 bpm, which suggests worsened CV status. These results argue for prospective studies analyzing the effect of more aggressive rate control on outcomes in such patients. With regard to the impact of permanent pacemaker implantation on patients undergoing TAVR, including those with AF, we found that mortality rates in those patients requiring pacemakers were increased more than 2-fold at 30 days. These results suggest that comorbidities associated with conduction abnormalities and pacemaker implantation may be causally related to increased mortality. For example, prior analysis has shown that implantation of new pacemakers is associated with higher rates of repeat hospitalization and mortality or repeat hospitalization at 1 year. 35 Further studies examining the role of pacemaker implantation on mortality in patients undergoing TAVR are required. With regard to overall functional status, several markers were worse in the AF groups, including decreased 6-minute walk test distance, especially in those patients with ventricular rates > 90 bpm, higher rates of renal failure, and bradyarrhythmias requiring pacemakers. These results suggest that physical vitality is reduced in AF patients after TAVR when compared with patients who were in SR at discharge, a hypothesis-generating observation. Further studies of newergeneration TAVRs and techniques are warranted to explore the association between TAVR and procedure type, development of AF, and clinical outcomes.
Frequency of cardiac rhythm monitoring may account for the difference between this study and others reporting stroke and mortality in AF patients after TAVR, as rhythm status in this study was determined with baseline and discharge ECGs. For example, Amat-Santos et al 31 noted no statistically significant difference in mortality with new-onset AF, which occurred in 31% of patients. However, all patients were on continuous cardiac monitors, and all but 1 patient experienced spontaneous, electric, or chemical cardioversion to SR during the hospitalization. Greater than 70% of patients experienced AF for <24 hours. Thus, patients in this trial would be less likely to be discharged in AF and possessed different characteristics from those in the present analysis, who were in AF at discharge and likely shouldered a larger AF burden. In another smaller, single-center trial of 389 total patients undergoing TAVR, Stortecky et al 34 noted increased mortality in 131 AF patients with TAVR (the majority of which were Medtronic CoreValves), most of whom had preexisting AF. Our results differ in noting the highest mortality occurred in patients with baseline SR/discharge AF, findings which may be related to the different burden of AF between study populations.
Clinical and Research Implications
AF is a comorbidity in patients undergoing TAVR that is associated with worse overall outcomes, including mortality. Patients who develop AF by discharge form a problematic group not only with regard to anticoagulation (eg, whether to anticoagulate and which medication to use) but also with regard to decisions regarding rate-control and rhythm-control strategies. Although β-blockers, amiodarone, and other drug options have shown some promise in treating postoperative AF, [36] [37] [38] it remains unclear the extent to which these are useful agents in managing TAVR patients.
The maintenance of SR suggests a protective effect in patients undergoing TAVR. Further research should be directed toward determining the extent to which AF-targeted therapy in patients undergoing TAVR can improve outcomes with strategies including refinement of anticoagulant therapy, rate-control, antiarrhythmic agents, and cardioversion. 17, 18 
Study Limitations
This study was a post hoc analysis of a prospective trial with adjudication of ECG and clinical outcome data, and ECGs were analyzed at discrete time points: baseline, discharge, and 1 year. Continuous cardiac rhythm monitoring was not available for this study. Thus, patients with a change in rhythm status or rate between admission and discharge, such as those who developed new-onset AF during hospitalization and subsequently converted to SR before discharge, were not included in the group of patients analyzed as having developed AF. Similarly, patients who may have developed AF after discharge were not included in the AF cohort. In addition, this study does not include details regarding history of AF or flutter in any of the patients, nor does it include details of antiarrhythmic or anticoagulant treatment while in the hospital or after discharge. Finally, although adjustments for several covariates were made, the potential for unmeasured confounders exists.
Conclusions
After TAVR, the presence of AF at discharge, and especially the conversion to AF with ventricular rates >90 bpm, is associated with an increase in early and late all-cause and CV mortality. Although it is evident that AF is associated with an increase in mortality in patients who undergo TAVR, it remains unclear whether effective treatment of AF rhythm or rate could reduce this increase in mortality. AF patients undergoing TAVR should be further studied for strategies that can improve clinical outcomes.
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